Back to all studies
RecruitingNCT07196501

Maintenance of Effect of NBI-1065845 for depression

The registry lists this study as recruiting. Study locations are listed in the United States, in Australia, in Canada, ... Confirm recruitment at each site. It is testing Maintenance of Effect of NBI-1065845 for depression.

DepressionDrugOver 18 Years
In plain English

Key information made simple

What is this study testing?

This study is testing whether NBI-1065845 may be useful for adults experiencing depression.

What would participation involve?

Participants may receive NBI-1065845, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Australia, in Bulgaria, and in Canada.

Who is it mainly for?

This study appears to be mainly for adults with depression.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record (opens in a new tab)
  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateStarted: August 18, 2025
Recruitment status
Recruiting
Enrollment listed in the registry
550
Sponsor
Neurocrine Biosciences
Sponsor type
Biotech company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, Australia, Canada, ...
Age range
Over 18 Years
Official registry ID
NCT07196501
Official title
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Maintenance of Effect of NBI-1065845 as an Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)

Want help reviewing this study?

Loading the security check...
Study ID: NCT07196501. We help you review the study, but cannot decide medical eligibility.

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

View official study record (opens in a new tab)

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

Australia · 3 sites
  • Neurocrine Clinical Site
    Carlton, Victoria
    Site status: Recruiting
  • Neurocrine Clinical Site
    Melbourne, Victoria
    Site status: Recruiting
  • Neurocrine Clinical Site
    Parkville, Victoria
    Site status: Recruiting
Bulgaria · 4 sites
  • Neurocrine Clinical Site
    Sofia
    Site status: Recruiting
  • Neurocrine Clinical Site
    Sofia
    Site status: Recruiting
  • Neurocrine Clinical Site
    Sofia
    Site status: Recruiting
  • Neurocrine Clinical Site
    Sofia
    Site status: Recruiting
Canada · 5 sites
  • Neurocrine Clinical Site
    Calgary, Alberta
    Site status: Recruiting
  • Neurocrine Clinical Site
    North Vancouver, British Columbia
    Site status: Recruiting
  • Neurocrine Clinical Site
    Kingston, Ontario
    Site status: Recruiting
  • Neurocrine Clinical Site
    Sherbrooke, Quebec
    Site status: Recruiting
  • Neurocrine Clinical Site
    Toronto
    Site status: Recruiting
Estonia · 3 sites
  • Neurocrine Clinical Site
    Tallinn
    Site status: Recruiting
  • Neurocrine Clinical Site
    Tallinn
    Site status: Recruiting
  • Neurocrine Clinical Site
    Tartu
    Site status: Recruiting
Italy · 4 sites
  • Neurocrine Clinical Site
    Milan
    Site status: Withdrawn
  • Neurocrine Clinical Site
    Roma
    Site status: Recruiting
  • Neurocrine Clinical Site
    Rome
    Site status: Recruiting
  • Neurocrine Clinical Site
    Torino
    Site status: Recruiting
Poland · 3 sites
  • Neurocrine Clinical Site
    Bialystok
    Site status: Recruiting
  • Neurocrine Clinical Site
    Bydgoszcz
    Site status: Recruiting
  • Neurocrine Clinical Site
    Gdansk
    Site status: Recruiting
Serbia · 3 sites
  • Neurocrine Clinical Site
    Belgrade
    Site status: Recruiting
  • Neurocrine Clinical Site
    Kovin
    Site status: Recruiting
  • Neurocrine Clinical Site
    Kragujevac
    Site status: Recruiting
South Korea · 4 sites
  • Neurocrine Clinical Site
    Ansan-si, Gyeonggi-do
    Site status: Recruiting
  • Neurocrine Clinical Site
    Seoul
    Site status: Recruiting
  • Neurocrine Clinical Site
    Seoul
    Site status: Recruiting
  • Neurocrine Clinical Site
    Seoul
    Site status: Recruiting
Spain · 3 sites
  • Neurocrine Clinical Site
    Alcorcón, Madrid
    Site status: Recruiting
  • Neurocrine Clinical Site
    Barcelona
    Site status: Recruiting
  • Neurocrine Clinical Site
    Barcelona
    Site status: Recruiting
Taiwan · 4 sites
  • Neurocrine Clinical Site
    Keelung
    Site status: Recruiting
  • Neurocrine Clinical Site
    Taipei
    Site status: Recruiting
  • Neurocrine Clinical Site
    Taipei
    Site status: Recruiting
  • Neurocrine Clinical Site
    Taipei
    Site status: Recruiting
United States · 24 sites
  • Neurocrine Clinical Site
    Oceanside, California
    Site status: Recruiting
  • Neurocrine Clinical Site
    Orange, California
    Site status: Recruiting
  • Neurocrine Clinical Site
    San Jose, California
    Site status: Recruiting
  • Neurocrine Clinical Site
    New Haven, Connecticut
    Site status: Recruiting
  • Neurocrine Clinical Site
    Miami Gardens, Florida
    Site status: Recruiting
  • Neurocrine Clinical Site
    Orlando, Florida
    Site status: Recruiting
  • Neurocrine Clinical Site
    Palm Bay, Florida
    Site status: Recruiting
  • Neurocrine Clinical Site
    Tampa, Florida
    Site status: Recruiting
  • Neurocrine Clinical Site
    Iowa City, Iowa
    Site status: Recruiting
  • Neurocrine Clinical Site
    Marrero, Louisiana
    Site status: Recruiting
  • Neurocrine Clinical Site
    O'Fallon, Missouri
    Site status: Recruiting
  • Neurocrine Clinical Site
    Albuquerque, New Mexico
    Site status: Recruiting
  • Neurocrine Clinical Site
    Glen Oaks, New York
    Site status: Recruiting
  • Neurocrine Clinical Site
    Charlotte, North Carolina
    Site status: Recruiting
  • Neurocrine Clinical Site
    Edmond, Oklahoma
    Site status: Recruiting
  • Neurocrine Clinical Site
    Oklahoma City, Oklahoma
    Site status: Recruiting
  • Neurocrine Clinical Site
    Philadelphia, Pennsylvania
    Site status: Recruiting
  • Neurocrine Clinical Site
    Austin, Texas
    Site status: Active Not Recruiting
  • Neurocrine Clinical Site
    Bellaire, Texas
    Site status: Recruiting
  • Neurocrine Clinical Site
    Friendswood, Texas
    Site status: Terminated
  • Neurocrine Clinical Site
    Stafford, Texas
    Site status: Recruiting
  • Neurocrine Clinical Site
    Wichita Falls, Texas
    Site status: Recruiting
  • Neurocrine Clinical Site
    Draper, Utah
    Site status: Recruiting
  • Neurocrine Clinical Site
    Roanoke, Virginia
    Site status: Recruiting
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study involving NBI-1065845, Placebo. Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.

Who might this study be for?

This study may concern people with depression; age range: Over 18 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by Neurocrine Biosciences, which appears to be a biotech company. Sponsor website: https://www.neurocrine.com. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as recruiting. Individual sites may have different statuses. The research team must confirm whether a site is open and whether you meet the criteria.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me